TY - JOUR
AU1 - Costa, Larissa
AU2 - Queiroz, Marcelo
AU3 - Barbosa, Felipe
AU4 - Nunes, Rafael
AU5 - Marin, José
AU6 - Dzik, Carlos
AU7 - Buchpiguel, Carlos
AB - European Journal of Nuclear Medicine and Molecular Imaging (2019) 46:1576–1577 https://doi.org/10.1007/s00259-019-04328-1 IMAGE OF THE MONTH Pseudoprogression on PSMA PET imaging of a mCRPC patient under anti-PD1 treatment 1 1,2 1 1 Larissa Bastos Costa & Marcelo Araujo Queiroz & Felipe de Galiza Barbosa & Rafael Fernandes Nunes & 1,2 3 1,2 José Flávio Gomes Marin & Carlos Dzik & Carlos Alberto Buchpiguel Received: 25 February 2019 /Accepted: 2 April 2019 /Published online: 22 April 2019 Springer-Verlag GmbH Germany, part of Springer Nature 2019 Ga-radiolabeled ligand with high affinity for prostate- stantial reduction of PSA levels (arrowheads in (D), (E), specific membrane antigen PET/CT (PSMA-PET) is an (F); short arrows in (G), (H), (I)). Two major hypotheses emerging modality for therapy response assessment in pros- might be raised considering previous reports of ADT for tate cancer (PCa), accurately detecting nodal, bone and viscer- PCa and immunotherapy for other cancers: (a) upregulation al metastases better than conventional imaging [1]. Therapy of PSMA molecular expression and (b) increased vascular monitoring after treatment remains troublesome, especially permeability induced by the recruitment of activated T cells when evaluating response to chemotherapy and androgen- as a first response to treatment [4, 5]. Hence, the different 
TI - Pseudoprogression on PSMA PET imaging of a mCRPC patient under anti-PD1 treatment
JF - European Journal of Nuclear Medicine and Molecular Imaging
DO - 10.1007/s00259-019-04328-1
DA - 2019-04-22
UR - https://www.deepdyve.com/lp/springer-journals/pseudoprogression-on-psma-pet-imaging-of-a-mcrpc-patient-under-anti-zrCm4sJjcT
SP - 1576
EP - 1577
VL - 46
IS - 7
DP - DeepDyve
ER -